文献速递骨质疏松与代谢性骨病

罗莫佐单抗治疗期间药物相关颌骨坏死风险

Risk of medication-related osteonecrosis of the jaw during romosozumab treatment.
PubMed 文献 · Osteoporos Int · 2026-06-16

该回顾性新用户活性对照倾向评分匹配队列研究在TriNetX全球协作网络比较了接受罗莫佐单抗与甲状旁腺激素类似物(特立帕肽或阿巴洛帕肽)治疗的女性,匹配后每组各15689例。随访1年期间,罗莫佐单抗组发生药物相关颌骨坏死(MRONJ)11例,PTH类似物组12例(HR 0.89,95%CI 0.39-2.01;log-rank p=0.78),绝对事件率分别为0.070%与0.076%。真实世界数据未显示罗莫佐单抗较PTH类似物在批准治疗窗内存在可检测的短期MRONJ风险增加。

要点

  • 罗莫佐单抗组1年MRONJ绝对事件率为0.070%,PTH类似物组为0.076%。
  • 两组MRONJ风险无显著差异(HR 0.89,95%CI 0.39-2.01;log-rank p=0.78)。
  • 因事件罕见,不能排除两组间存在小幅差异。

核心结论

  • 真实世界数据未显示罗莫佐单抗较PTH类似物在批准治疗窗内存在可检测的短期MRONJ风险增加。
  • 因事件罕见,两组间不能排除存在小幅差异。

研究设计与样本

  • 回顾性新用户活性对照倾向评分匹配队列研究,数据来源于TriNetX全球协作网络。
  • 比较接受罗莫佐单抗与甲状旁腺激素类似物(特立帕肽或阿巴洛帕肽)治疗的女性。
  • 纳入年龄≥18岁、无既往颌骨坏死、颌骨炎症性疾病、口腔/头颈癌或放射暴露且近期无化疗暴露的女性。
  • 经1:1倾向评分匹配后,每组各15689例患者。

主要发现

  • 随访1年期间,罗莫佐单抗组发生MRONJ 11例,PTH类似物组12例(HR 0.89,95%CI 0.39-2.01;log-rank p=0.78)。
  • 两组MRONJ绝对事件率分别为0.070%与0.076%。
  • 阳性对照结局高钙血症在罗莫佐单抗组发生更少(HR 0.66,95%CI 0.58-0.75)。

临床怎么用

  • 在批准治疗窗内使用罗莫佐单抗时,短期MRONJ风险与PTH类似物相比未见可检测的增加。
  • 因MRONJ事件罕见,临床仍需关注个体风险并持续监测。

局限性

  • MRONJ事件罕见,不能排除两组间存在小幅差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Medication-related osteonecrosis of the jaw (MRONJ) is a rare but clinically important adverse event in antiresorptive osteoporosis care. The most recently approved osteoporosis medication, romosozumab, has a dual mechanism, combining antiresorptive and osteoanabolic effects. Thus, concern exists regarding a possible risk for MRONJ with romosozumab, although current evidence is limited mainly to isolated case reports. We performed a retrospective new-user active comparator propensity score-matched cohort study in the TriNetX Global Collaborative Network comparing women treated with romosozumab vs. parathyroid hormone (PTH) analogs (teriparatide or abaloparatide). Women aged ≥ 18 years with no prior osteonecrosis, jaw inflammatory disease, oral/head-neck cancer, or radiation exposure and no recent exposure to chemotherapy were eligible. After 1:1 propensity score matching, 15,689 patients remained in each cohort. During 1 year of follow-up, MRONJ occurred in 11 romosozumab-treated patients and 12 PTH analog-treated patients (hazard ratio [HR] 0.89, 95% CI 0.39-2.01; log-rank p = 0.78). Absolute event rates were very low in both groups (0.070% vs. 0.076%). As expected, the positive control outcome of hypercalcemia occurred less often with romosozumab (HR 0.66, 95% CI 0.58-0.75). These real-world data do not indicate a detectable excess short-term MRONJ risk with romosozumab compared with PTH analogs over the approved treatment window, although modest differences cannot be excluded because events were rare.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Stokar J, Szalat A. Risk of medication-related osteonecrosis of the jaw during romosozumab treatment. Osteoporos Int. 2026. PMID: 42303774. doi:10.1007/s00198-026-08109-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。